Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
Legacy MEDSearch
SEPTEMBER 27, 2022
Food and Drug Administration (FDA) 510(k) clearance for its CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-III. Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry.
Let's personalize your content